Paulson & CO. Inc. bought a new stake in shares of Entellus Medical, Inc. (NASDAQ:ENTL) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 102,702 shares of the medical technology company’s stock, valued at approximately $1,701,000. Paulson & CO. Inc. owned 0.40% of Entellus Medical at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ENTL. Frontier Capital Management Co. LLC increased its stake in Entellus Medical by 85.0% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock valued at $14,347,000 after buying an additional 397,953 shares during the period. Tekla Capital Management LLC acquired a new position in Entellus Medical during the 2nd quarter valued at about $5,655,000. Nicholas Company Inc. increased its stake in Entellus Medical by 1,052.3% during the 2nd quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after buying an additional 226,190 shares during the period. Grandeur Peak Global Advisors LLC increased its stake in Entellus Medical by 868.1% during the 1st quarter. Grandeur Peak Global Advisors LLC now owns 212,491 shares of the medical technology company’s stock valued at $2,932,000 after buying an additional 190,541 shares during the period. Finally, Vanguard Group Inc. increased its stake in Entellus Medical by 77.8% during the 1st quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after buying an additional 185,833 shares during the period. 70.27% of the stock is currently owned by hedge funds and other institutional investors.

In other Entellus Medical news, VP Timothy B. Petrick sold 2,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $20.01, for a total transaction of $40,020.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Brian E. Farley sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total transaction of $791,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 79,650 shares of company stock worth $1,510,252. Corporate insiders own 7.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/paulson-co-inc-takes-position-in-entellus-medical-inc-entl/1639216.html.

Entellus Medical (NASDAQ:ENTL) last released its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The business’s revenue for the quarter was up 18.0% on a year-over-year basis.

Several equities analysts have commented on the stock. Canaccord Genuity reissued a “hold” rating and set a $17.00 target price on shares of Entellus Medical in a research note on Tuesday. BidaskClub cut shares of Entellus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Monday, October 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $21.00 target price on shares of Entellus Medical in a research note on Tuesday, August 22nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $21.86.

Entellus Medical Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical, Inc. (NASDAQ:ENTL).

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.